Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer. This evidence concerns the gene RPS6KB1 and triple-negative breast carcinoma.